Review of pharmacoeconomic evaluation of genotype-guided antiplatelet therapy
Publication in refereed journal


Times Cited
Web of Science17WOS source URL (as at 25/10/2020) Click here for the latest count
Altmetrics Information
.

Other information
AbstractIntroduction: Clopidogrel is an antiplatelet agent widely prescribed for acute coronary syndrome (ACS), and it is activated by the CYP enzyme system to active metabolite. CYP2C19 loss-of-function (LOF) allele(s) affect the responsiveness of clopidogrel, but not the new antiplatelet agents (prasugrel and ticagrelor). We reviewed the pharmacoeconomic studies on genotype-guided use of new antiplatelet agents.
All Author(s) ListJiang MH, You JHS
Journal nameExpert Opinion on Pharmacotherapy
Detailed descriptionEarly Online.
Year2015
Month4
Day1
Volume Number16
Issue Number5
PublisherINFORMA HEALTHCARE
Pages771 - 779
ISSN1465-6566
eISSN1744-7666
LanguagesEnglish-United Kingdom
Keywordsclopidogrel; cost-effectiveness; CYP2C19; pharmacogenetics; prasugrel; ticagrelor
Web of Science Subject CategoriesPharmacology & Pharmacy

Last updated on 2020-26-10 at 00:28